CDH17 Mouse Monoclonal Antibody
- Known as:
- CDH17 Mouse Monoclonal Antibody
- Catalog number:
- BIN-001015-M03
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- CDH17 Mouse Monoclonal Antibody
Related genes to: CDH17 Mouse Monoclonal Antibody
- Gene:
- CDH17 NIH gene
- Name:
- cadherin 17
- Previous symbol:
- -
- Synonyms:
- HPT-1, cadherin
- Chromosome:
- 8q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1997-02-10
- Date modifiied:
- 2016-01-15
Related products to: CDH17 Mouse Monoclonal Antibody
Related articles to: CDH17 Mouse Monoclonal Antibody
- Dynein axonemal assembly factors (DNAAF) are essential for the assembly and transport of dynein motor complexes, which are crucial for the movement of cilia. Mutations in genes encoding these proteins often lead to motile ciliopathies called primary ciliary dyskinesia (PCD). In humans, loss-of-function mutations of Cilia and flagella-associated protein 300 (CFAP300, also known as DNAAF17) have been reported to cause PCD. The function of CFAP300 during embryogenesis, however, has not been reported. We carried out functional studies using zebrafish to understand its function during vertebrate development. - Source: PubMed
Publication date: 2026/05/01
Nayak UsharaniSahoo KalyaniBarrodia PraveenSwain Rajeeb K - BI 905711, a TRAILR2/CDH17 bispecific antibody, demonstrated preclinical apoptotic pathway activation and antitumor activity. Two phase Ia/Ib studies tested BI 905711 monotherapy (NCT04137289) or combination therapy (NCT05087992) in advanced, refractory gastrointestinal (GI) cancers. - Source: PubMed
Publication date: 2026/04/15
Harding James JHofheinz RalfÉlez ElenaKuboki YasutoshiRasco Drew WCecchini MichaelShen LinHe MinArchuadze ShorenaChhaya NirajHaderk FranziskaMészáros LisaWölke StefanKatakabe TetsuyaLorence Robert MVan Cutsem EricKopetz ScottPant Shubham - - Source: PubMed
Publication date: 2026/04/02
Fernandez BenjaminLopez LéaMatis ThibautDabernat SandrineAmintas Samuel - Chemoresistance greatly impairs the effectiveness of chemotherapy in gastric cancer (GC) patients. According to our prior results, Cadherin-17 (CDH17) contributes to chemoresistance in GC through activating the Wnt/β-catenin pathway; however, its specific molecular mechanisms require further elucidation. We compared the Wnt/β-catenin pathway activation levels between cisplatin (DDP)-resistant GC cell lines and their parental cell lines. Subsequently, we carried out loss-of-function and gain-of-function tests to investigate CDH17 for its effect on regulating β-catenin expression, nuclear transport, as well as transcriptional activity within DDP-resistant GC cells. Additionally, CDH17 was examined for its role in the expression of four ABC transporters using molecular assays. Finally, rescue experiments were carried out using the Wnt signaling pathway agonist CP21R7 and inhibitor IWR-1 to elucidate the specific mechanism of CDH17 in promoting chemotherapy resistance of GC cells. The results showed that the activation level of the Wnt/β-catenin signaling pathway was significantly elevated in DDP-resistant GC cell lines compared to their parental cell lines. Silencing CDH17 resulted in reduced expression, impaired nuclear translocation, and decreased transcriptional activity of β-catenin, whereas overexpression of CDH17 had the opposite effects. Notably, CDH17 was shown to specifically regulate the expression of ABCB1 (protein name: P-glycoprotein, P-gp) in resistant cells, with no observable impact on the other three ABC transporters (ABCC1, ABCG2, and ABCC2) examined. Importantly, treatment with IWR-1 effectively reversed the enhancing effect of CDH17 overexpression on P-gp protein expression, as well as its suppressive effects on DDP accumulation and chemosensitivity. Conversely, administration of CP21R7 attenuated the inhibitory consequences of CDH17 silencing on P-gp expression, DDP efflux, and drug resistance. In conclusion, CDH17 promotes the expression and nuclear translocation of β-catenin in GC cells, leading to activation of the Wnt/β-catenin signaling pathway, which subsequently upregulates ABCB1/P-gp expression and enhances cellular capacity for DDP efflux. These findings imply that targeting CDH17 could be a potential strategy for overcoming chemotherapy resistance in GC. - Source: PubMed
Publication date: 2026/03/23
Liu MengHan ZhengZhong ZiqiangTan JieZhu QingxiChen WeiHuang ShashaChen XiaoliTian Xia - Barrett's esophagus (BE) represents a critical precancerous lesion arising from chronic gastroesophageal reflux disease (GERD), with significant risk of progression to esophageal adenocarcinoma. Despite advances in transcriptomic technologies, including single-cell RNA sequencing (scRNA-seq), the molecular mechanisms underlying the GERD-to-BE transition remain incompletely understood. Comprehensive transcriptomic profiling at both bulk and, prospectively, single-cell resolution is essential for identifying disease-driving molecular signatures and cellular heterogeneity. This study aimed to systematically characterize the transcriptomic landscape of GERD and Barrett's esophagus through integrative bulk RNA-sequencing analysis, with the goal of establishing a foundational framework for future single-cell transcriptomic investigations. - Source: PubMed
Publication date: 2026/03/14
Jiang ShanshanWang XiuminChen YujunDong WeihuaXu JingZhang ChunlanZhou ChunYu Chun